<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01136252</url>
  </required_header>
  <id_info>
    <org_study_id>ZAPA-01/EudraCT 2009-017429-21</org_study_id>
    <secondary_id>2009-017429-21</secondary_id>
    <nct_id>NCT01136252</nct_id>
  </id_info>
  <brief_title>Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration</brief_title>
  <official_title>Open-label Clinical Trial to Evaluate Safety and Efficacy of Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Non-responders to the Conventional Treatment With Ranibizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adalimumab is a humanized recombinant monoclonal antibody fragment targeted against tumor
      necrosis factor. This study will assess the safety and efficacy of intravitreal adalimumab
      administered in patients with choroidal neovascularization secondary to age-related macular
      degeneration non-responders to the conventional treatment with intravitreal ranibizumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients proportion with electroretinogram alterations</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in retinal thickness measured by ocular coherence tomography</measure>
    <time_frame>once a month to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in best corrected visual acuity</measure>
    <time_frame>once a month to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>until 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <condition>Choroidal Neovascularization</condition>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Intravitreal adalimumab injection (0,1 ml= 50 mcg) in the eye of the included patients. Patients will be followed up every week for a total of 4 weeks, and after every month until 6 months. If it is necessary, repeat the injection every month, maximum three months</description>
    <arm_group_label>Adalimumab</arm_group_label>
    <other_name>HumiraÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Choroidal neovascularization secondary to age-related macular degeneration non-responders
        to the conventional treatment with ranibizumab (active choroidal neovascularization after
        loading phase of one injection per month for three consecutive months, followed by a
        maintenance phase with 5 injections in the last 12 months or 3 injections in the last 6
        months

        Exclusion Criteria:

          -  Only one functional eye

          -  Hypersensitivity to adalimumab or any component of the formulation

          -  Previous systemic treatment with adalimumab

          -  Cancer

          -  Life expectancy &lt;1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel A Zapata, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Servicio de Oftalmologia. Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2010</study_first_submitted>
  <study_first_submitted_qc>June 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2010</study_first_posted>
  <last_update_submitted>March 16, 2012</last_update_submitted>
  <last_update_submitted_qc>March 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

